<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02810119</url>
  </required_header>
  <id_info>
    <org_study_id>WP-LO2A-02</org_study_id>
    <nct_id>NCT02810119</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Conjunctivochalasis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Pilot Study to Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Moderate to Severe Conjunctivochalasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ocuwize LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ocuwize LTD</source>
  <brief_summary>
    <textblock>
      A Randomized, Double-Blind, Placebo-Controlled, Pilot Study to Evaluate the Efficacy and&#xD;
      Safety of LO2A Eye Drops in Patients with Moderate to Severe Conjunctivochalasis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 2a, randomized, placebo-controlled, pilot study in up to 21 adult patients with&#xD;
      moderate to severe CCh. Eligible patients will be randomly assigned in a 2:1 (active:placebo)&#xD;
      ratio to one of two treatment groups, LO2A or placebo.&#xD;
&#xD;
      This study with 4 visits, will consist of a screening period of up to 2 weeks and a 3-month&#xD;
      treatment period (topical, OU, QID application of eye drops).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change from baseline in lissamine green conjunctival staining (LGCS) score</measure>
    <time_frame>baseline and 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in the lid-parallel conjunctival fold (LIPCOF) grade score at 1 and 3 months compared to baseline</measure>
    <time_frame>baseline, 1 month and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in LGCS score</measure>
    <time_frame>baseline and 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in tear-film break up time (TFBUT) compared to baseline at 1 and 3 months</measure>
    <time_frame>baseline, 1 month and 3 months]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in ocular surface disease index (OSDI) questionnaire score compared to baseline at 1 and 3 months</measure>
    <time_frame>baseline, 1 month and 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Conjunctivochalasis</condition>
  <arm_group>
    <arm_group_label>LO2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sodium Hyaluronate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Controlled Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LO2A</intervention_name>
    <arm_group_label>LO2A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo-Controlled Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female of any race and ≥ 18 years of age.&#xD;
&#xD;
          2. Willing and able to provide voluntary written informed consent.&#xD;
&#xD;
          3. Moderate to severe conjunctivochalasis defined by:&#xD;
&#xD;
               -  LIPCOF score ≥ 2; and&#xD;
&#xD;
               -  Lissamine green conjunctival staining score ≥ 5 according to National Eye&#xD;
                  Institute/Industry Workshop report.&#xD;
&#xD;
          4. Willing and able to adhere to the study visit schedule and other protocol&#xD;
             requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has concurrent, uncontrolled medical condition, or psychiatric illness which&#xD;
             could place him/her at unacceptable risk, including, but not limited to:&#xD;
&#xD;
               -  Subject has been diagnosed or treated for another malignancy within 3 years of&#xD;
                  screening, except in situ malignancy, or low-risk prostate, skin or cervix cancer&#xD;
                  after curative therapy.&#xD;
&#xD;
               -  A co-morbid condition which, in the view of the Investigators, renders the&#xD;
                  subject at high risk from treatment complications.&#xD;
&#xD;
          2. Subjects with pterygium.&#xD;
&#xD;
          3. Subjects with active, allergic keratoconjunctivitis, or conjunctivitis of infectious&#xD;
             origin.&#xD;
&#xD;
          4. Subjects with blepharitis requiring treatment.&#xD;
&#xD;
          5. Subjects with a history of surgery affecting the eye surface, as well as eye injuries&#xD;
             within 3 months of screening.&#xD;
&#xD;
          6. Subjects currently using any topical ophthalmic treatment (including medications for&#xD;
             glaucoma) or over-the-counter (OTC) solutions, artificial tears, gels or scrubs, and&#xD;
             cannot discontinue these medications for the duration of the trial.&#xD;
&#xD;
          7. Subjects who have used any of the following medications or treatments:&#xD;
&#xD;
               -  LASIK or PRK surgery within 12 months of Visit 1.&#xD;
&#xD;
               -  Use of contact lenses within 7 days of Visit 1.&#xD;
&#xD;
               -  Punctal plug insertion within 30 days of Visit 1.&#xD;
&#xD;
               -  Use of topical or systemic cyclosporine within 30 days of Visit 1.&#xD;
&#xD;
               -  Use of medications known to cause ocular drying (e.g. antihistamines, sleep aids,&#xD;
                  etc.), unless at a stable dose, within 30 days of Visit 1.&#xD;
&#xD;
          8. Known hypersensitivity to sodium hyaluronate or any LO2A excipients (glycerol and&#xD;
             Carbomer 981).&#xD;
&#xD;
          9. Active abuse of alcohol or drugs.&#xD;
&#xD;
         10. Any condition, which in the opinion of the Investigator, would place the patient at an&#xD;
             unacceptable risk if participating in the study protocol.&#xD;
&#xD;
         11. Participation in a clinical trial of an investigational (unapproved) drug or device&#xD;
             within 1 month prior to screening or scheduled to receive another investigational drug&#xD;
             or device during this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Barzilai MC</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>June 19, 2016</study_first_submitted>
  <study_first_submitted_qc>June 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2016</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Final Data report will be publish when the study will be finalized</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

